Radioligand therapy is transforming oncology by delivering targeted radiation directly to tumors while sparing healthy tissue. Recent approvals and rapid innovation in alpha- and beta-emitting isotopes have accelerated clinical momentum, yet many programs still face challenges including heterogeneous target expression, treatment resistance, limited radiation range and suboptimal tumor microenvironments that constrain therapeutic efficacy. This webinar explores how combination strategies can address these barriers and attendees can register to learn practical approaches for building effective regimens.
Combination strategies offer a powerful path forward.
By integrating radioligand therapy with complementary modalities such as targeted therapies, chemotherapy, DNA damage repair inhibitors, external beam radiation and immunotherapy, researchers can amplify DNA damage, sensitize tumors, enhance target expression and stimulate anti-tumor immune responses. However, realizing these benefits requires careful experimental planning, biologically relevant preclinical models, quantitative imaging and dosimetry and thoughtful safety assessment to balance efficacy with toxicity.
In this webinar, the featured speaker will explore the scientific rationale and translational tools needed to design and evaluate effective radioligand therapy combinations. Attendees will gain practical insights into mechanism-based pairing strategies, model selection, imaging biomarkers, dosing considerations and emerging clinical trends that help de-risk development and accelerate programs from discovery to clinic.
Register for this webinar to learn how radioligand therapy combination strategies can improve efficacy through translational study design, imaging and safety-informed dosing.
Speaker
Julian Goggi, PhD, Director, Discovery Research, Perceptive Discovery
Julian Goggi, PhD, is a Translational Scientist with over 20 years of experience in radiopharmaceutical research and development, specializing in the development of radioligand therapies and diagnostic radiopharmaceuticals across oncology, neurology and metabolic diseases. He has held senior roles in Europe and Asia, managing multidisciplinary teams and collaborations, and has authored over 60 peer-reviewed publications. He is currently serving as Director and Scientific Lead at Perceptive Inc, overseeing IND-enabling studies for radioligand therapy development.
Message PresenterWho Should Attend?
This webinar will appeal to:
- Chief Scientific Officers (CSOs) and Heads of R&D seeking to de-risk radioligand therapy and targeted therapeutic programs
- Translational Scientists
- Oncology Drug Developers
- Radiopharmaceutical and Radiochemistry teams
- Preclinical Pharmacology and Imaging Researchers
- Clinical Development and Translational Medicine Leaders
- Biotech and pharma professionals advancing RLT or theranostic programs
What You Will Learn
Attendees will be able to:
- Understand the biological mechanisms that limit radioligand therapy efficacy
- Identify combination partners that enhance target expression and tumor radiosensitivity
- Leverage DNA damage repair inhibitors, chemotherapy and immune checkpoint inhibitors to drive synergistic responses
- Select translationally relevant preclinical models (syngeneic, humanized and immunocompetent) for combination studies
- Use imaging and dosimetry biomarkers to quantify response and optimize timing
- Anticipate safety, toxicity and scheduling challenges in multi-modal regimens
- Design smarter studies that improve clinical predictability and accelerate decision-making
Xtalks Partner
Perceptive Discovery
Perceptive Discovery bridges the gap between preclinical insights and early clinical success, providing the expertise and high-quality data needed to advance innovation with confidence. With deep expertise in advanced imaging, radiochemistry, and translational science, we specialize in supporting drug development programs across CNS, oncology, and radioligand therapy. Our integrated approach combines rigorous scientific analysis, state-of-the-art imaging platforms, and multidisciplinary expertise to deliver data that drives smarter decisions, reduces risk, and accelerates timelines from preclinical to first-in-human studies.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account